Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

AimTo determine the plasma and saliva levels of IL-6 in patients with bisphosphonate-related osteonecrosis of the jaws (BRONJ) and to investigate whether there is a correlation between more advanced stages of BRONJ and levels of IL-6.Material and methodsWe studied three groups: group 1 consisted of 30 patients with BRONJ due to intravenous bisphosphonates (ivBP), group 2 consisted of 25 patients treated with ivBP but without BRONJ, and group 3 consisted of 15 healthy controls. In each case, we assayed plasma and saliva IL-6 samples using an ELISA test.ResultsSignificantly, higher IL-6 values were found in both saliva and plasma in group 1 vs groups 2 and 3 (P  0.05), type of tumor, BRONJ location, etiology of BRONJ, or disease stage (P > 0.05). We found higher plasma and saliva IL-6 values in the more advances stages of BRONJ, although the differences were not statistically significant.ConclusionsPlasma and saliva IL-6 values were higher in our patients with BRONJ than in controls and therefore might be a useful tool for monitoring the severity of BRONJ.

Original publication




Journal article


Oral diseases

Publication Date





446 - 452


Oral Medicine, Head Service of Stomatology and Maxillofacial Surgery, University of Valencia, University General Hospital, Valencia, Spain.


Saliva, Humans, Diphosphonates, Interleukin-6, Aged, Female, Male, Bisphosphonate-Associated Osteonecrosis of the Jaw